Literature DB >> 34676042

Discovery of Dolastatinol: A Synthetic Analog of Dolastatin 10 and Low Nanomolar Inhibitor of Tubulin Polymerization.

Hodaya Gutman1, Andrii Bazylevich1, Chandrashekhar Prasad1, Ortal Dorfman1, Arkadi Hesin2, Vered Marks1, Leonid Patsenker1, Gary Gellerman1.   

Abstract

We developed a highly potent anticancer agent, dolastatinol, which is a methylene hydroxyl derivative of dolastatin 10. Dolastatinol is a synthetic analog of dolastatin 10, synthesized by a solid-phase peptide Fmoc chemistry protocol on 2-chlorotrityl chloride resin utilizing a pH-triggering self-immolative monosuccinate linker. The introduction of the C-terminus hydroxyl methylene functionality preserves the anticancer properties of the parent dolastatin 10, including strong suppression of the cell proliferation, migration, high cytotoxicity. Our research establishes a new facile route toward the further development of C-terminus-modified dolastatin-10-based microtubule inhibitors for anticancer treatment.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 34676042      PMCID: PMC8521654          DOI: 10.1021/acsmedchemlett.1c00432

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  27 in total

Review 1.  Design and synthesis of analogues of natural products.

Authors:  Martin E Maier
Journal:  Org Biomol Chem       Date:  2015-05-21       Impact factor: 3.876

2.  Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.

Authors:  U Vaishampayan; M Glode; W Du; A Kraft; G Hudes; J Wright; M Hussain
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

3.  Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.

Authors:  P Verdier-Pinard; J A Kepler; G R Pettit; E Hamel
Journal:  Mol Pharmacol       Date:  2000-01       Impact factor: 4.436

4.  Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E conjugates.

Authors:  Kelly E Burns; Matthew K Robinson; Damien Thévenin
Journal:  Mol Pharm       Date:  2015-03-13       Impact factor: 4.939

5.  Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10.

Authors:  R L Bai; G R Pettit; E Hamel
Journal:  Biochem Pharmacol       Date:  1990-10-15       Impact factor: 5.858

6.  Dual-drug RGD conjugates provide enhanced cytotoxicity to melanoma and non-small lung cancer cells.

Authors:  Y Gilad; E Noy; H Senderowitz; A Albeck; M A Firer; G Gellerman
Journal:  Biopolymers       Date:  2016-03       Impact factor: 2.505

7.  Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton.

Authors:  Marcel N A Bijman; Geerten P van Nieuw Amerongen; Nancy Laurens; Victor W M van Hinsbergh; Epie Boven
Journal:  Mol Cancer Ther       Date:  2006-09       Impact factor: 6.261

8.  Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains.

Authors:  Julien Dugal-Tessier; Stuart D Barnscher; Akira Kanai; Brian A Mendelsohn
Journal:  J Nat Prod       Date:  2017-09-08       Impact factor: 4.050

9.  Characterization of Triple-Negative Breast Cancer MDA-MB-231 Cell Spheroid Model.

Authors:  Zhaoming Huang; Panpan Yu; Jianhui Tang
Journal:  Onco Targets Ther       Date:  2020-06-11       Impact factor: 4.147

Review 10.  Orchestrating mitochondria in neurons: Cytoskeleton as the conductor.

Authors:  Carlos Cardanho-Ramos; Andreia Faria-Pereira; Vanessa Alexandra Morais
Journal:  Cytoskeleton (Hoboken)       Date:  2019-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.